Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
ID: 354240Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354240

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted May 16, 2024 12:00 AM
  4. 4
    Due Oct 7, 2024 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)". This grant aims to support innovative strategies that target and manipulate brain cell subtypes affected by aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). The goal is to develop and utilize sophisticated tools to precisely target disease-relevant cell subtypes in aged and degenerating mammalian brains, and to monitor and manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animal models. The grant provides up to 2 years of support for pilot activities (R61 phase) and up to 3 years of support for implementation activities including hypothesis testing (R33 phase). Eligible applicants include various institutions and organizations. The deadline for applications is October 7, 2024. For more information, visit the grant opportunity website.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-AG-25-024-Full-Announcement.html
5/17/2024
Similar Opportunities
Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)". This grant aims to support the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). The goal is to de-risk subsequent translational research and accelerate the development of novel therapies for ADRD. The grant will provide support for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidates in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. The impact of the target modulation will be measured and cross-validated in different modalities across collaborating laboratories. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. The deadline for applications is November 8, 2024. For more information, please visit the [grant opportunity website](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-011.html).
Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)". This grant aims to support the development and validation of novel human cellular models that are clinically and/or pathophysiologically relevant to ADRD. These cellular models should capture the various pathologies and multiple cell types observed in ADRDs. The validation process should include internal, face, construct, and predictive validation to the extent possible. The goal of these models is to aid in therapy development and enhance our understanding of human disease mechanisms and predisposition to developing neurodegenerative dementias. The models should be novel, complex, and address existing gaps in currently available models. Multidisciplinary teams are highly encouraged, and leveraging existing NIH cell repository resources is also encouraged. The grant has a funding ceiling of $500,000 and does not require cost sharing or matching. The deadline for applications is October 21, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-032.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-032.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)". This grant is in the category of Health and falls under the funding instrument type of Grant. The grant does not require cost sharing or matching. The opportunity is discretionary and falls under CFDA number 93.866. The purpose of this grant is to support investigations into the cellular and molecular mechanisms of how and why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes in dementias with multiple etiologies. The grant aims to identify the mechanisms of co-pathology cellular and molecular interactions across brain regions and time, as well as determine the events that lead to worse phenotypic outcomes. The investigations should focus on a minimum of two relevant co-pathologies, such as tau, alpha-synuclein, TDP-43, TMEM106B, and vascular, with optional risk factors and co-morbidities. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant has an award ceiling of $500,000. The closing date for applications is October 4, 2024, and the archive date is November 9, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)". This grant aims to support research projects that collect pilot data to test pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline, Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The funding opportunity seeks to stimulate studies that enhance trial design and methods. The grant does not require cost sharing or matching. The maximum award ceiling is $325,000. The eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for applications is November 18, 2024. For more information and to apply, visit the following link: [Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)". This grant aims to support the development and implementation of clinical trials for pharmacological and non-pharmacological interventions to prevent and treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline, Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The grant also aims to stimulate studies that enhance trial design and methods. The funding instrument for this opportunity is a grant, and there is no cost sharing or matching requirement. The category of funding activity is health, and the opportunity falls under the discretionary category. The CFDA number associated with this grant is 93.866. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the federal government, faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities (HBCUs), Indian/Native American tribal governments, non-domestic entities (foreign organizations), regional organizations, tribally controlled colleges and universities (TCCUs), and U.S. territories or possessions. The closing date for applications is October 17, 2024, and the archive date is November 22, 2024. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-011.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-011.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.